Hhlr Advisors portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Hhlr Advisors reported a $832M portfolio of 35 positions to the SEC as of the end of Q2 2026. Its largest positions are LEGN, FUTU, AVBP. During the quarter it exited Beone Medicines.
Sections with a free account
What changed this quarter
23 positions with a change (4 new, 6 added to, 6 trimmed, 7 sold); also, 2 entered through an IPO, 2 exited through an acquisition or merger. 6 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedAlamar BiosciencesALMR3.1% of the portfolio
- Newly listedOdyssey TherapeuticsODTX1.9% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Beone Medicines−18.4 ppof portfolioSold out18.4% → —
- PDD Holdings−88%fewer sharesReduced25.4% → 4.6%
- Alibaba Group Holding−93%fewer sharesReduced18.4% → 2.1%
- Vipshop Holdings+2,683%more sharesIncreased0.1% → 5.5%
- Futu Holdings+25%more sharesIncreased11.6% → 19.9%
- KE Holdings−48%fewer sharesReduced3.8% → 3.9%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Legend BiotechLEGN20.8%
- Futu HoldingsFUTU19.9%
- Arrivent BiopharmaAVBP16.4%
- Marvell TechnologyMRVL5.8%
- Vipshop HoldingsVIPS5.5%
- PDD HoldingsPDD4.6%
- KE HoldingsBEKE3.9%
- Cytek BiosciencesCTKB3.5%
- Alamar BiosciencesALMR3.1%
- Alibaba Group HoldingBABA2.1%
- Odyssey TherapeuticsODTX1.9%
- Yatsen HoldingYSG1.9%
- NovaBridge BiosciencesNBP1.4%
- Contineum TherapeuticsCTNM1.3%
- MAZE TherapeuticsMAZE1.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 51%
- ● Financials 20%
- ● Consumer Discretionary 12%
- ● Information Technology 10%
- ● Real Estate 4%
- ● Consumer Staples 2%
- ● Industrials 1%
- ● Communication Services 1%
How its portfolio changed (8 quarters)
Q2 2026: 35
Q2 2026: 86%
Q2 2026: 29.2%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (medium confidence).
The data, as reported: HHLR ADVISORS, LTD. (CRD 166112): Exempt reporting adviser to private funds, based in Singapore; 7.B private funds: 2 hedge (gross assets $22.1 bn) · 13F: 47% of the portfolio was already held when the stock started trading
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Sirios Capital ManagementInvestment firm · $822M
- Kora ManagementInvestment firm · $843M
- Parsifal Capital ManagementInvestment firm · $817M
- Schwerin Boyle Capital ManagementInvestment firm · $816M
- Light Street Capital ManagementInvestment firm · $851M
- Tri Locum PartnersInvestment firm · $813M